Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bausch + Lomb, Luminodx, Canary Oncoceutics, Nyxoah, Pangia Biotech.
Edap TMS SA recently published data showing that its Focal One high intensity focused ultrasound technology is non-inferior to radical prostatectomy as a first-line treatment for localized prostate cancer. The company is also working towards gaining approval for the technology as a therapy for endometriosis.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Roche, Zimmer Biomet.
Relation Therapeutics Ltd. has delivered the first commercial validation of its combined wet lab/in silico platform for homing in on disease-related genes in the thick of the genome, signing two collaboration agreements with GSK plc, with a potential value of $200 million per target.
Capstan Medical Inc. closed an oversubscribed series C fundraising round that brought in $110 million for the structural heart-focused company. Capstan aims to combine valve implants, advanced catheter technology and a robotic platform to facilitate expanded minimally invasive treatment options for patients with heart valve disease.
The fact that both the U.S. Federal Trade Commission and the Department of Justice have oversight of mergers and acquisitions is something of a regulatory oddity. But David Balto, an attorney specializing on antitrust matters, told BioWorld that this may change in 2025 thanks to support for such a move from both Congress and the White House.
RSS
